MX342250B - Tratamiento de cánceres resistentes a antagonistas notch1, mediante el uso de antagonistas notch3. - Google Patents

Tratamiento de cánceres resistentes a antagonistas notch1, mediante el uso de antagonistas notch3.

Info

Publication number
MX342250B
MX342250B MX2012003851A MX2012003851A MX342250B MX 342250 B MX342250 B MX 342250B MX 2012003851 A MX2012003851 A MX 2012003851A MX 2012003851 A MX2012003851 A MX 2012003851A MX 342250 B MX342250 B MX 342250B
Authority
MX
Mexico
Prior art keywords
methods
treating cancer
notch
notch antagonists
antagonists
Prior art date
Application number
MX2012003851A
Other languages
English (en)
Other versions
MX2012003851A (es
Inventor
Christian W Siebel
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2012003851A publication Critical patent/MX2012003851A/es
Publication of MX342250B publication Critical patent/MX342250B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a métodos para el tratamiento del cáncer en general y leucemia en particular, utilizando antagonistas de Notch1 y Notch3 solos o en combinación. También se proporcionan composiciones y métodos para el tratamiento y diagnóstico de tipos de cáncer asociados a Notch.
MX2012003851A 2009-09-30 2010-09-29 Tratamiento de cánceres resistentes a antagonistas notch1, mediante el uso de antagonistas notch3. MX342250B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24729809P 2009-09-30 2009-09-30
PCT/US2010/050610 WO2011041336A2 (en) 2009-09-30 2010-09-29 Methods of treating cancer using notch antagonists

Publications (2)

Publication Number Publication Date
MX2012003851A MX2012003851A (es) 2012-05-08
MX342250B true MX342250B (es) 2016-09-22

Family

ID=43127684

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003851A MX342250B (es) 2009-09-30 2010-09-29 Tratamiento de cánceres resistentes a antagonistas notch1, mediante el uso de antagonistas notch3.

Country Status (21)

Country Link
US (1) US9200071B2 (es)
EP (1) EP2483311B1 (es)
JP (3) JP6025563B2 (es)
KR (1) KR101782180B1 (es)
CN (1) CN102630229B (es)
AU (1) AU2010300747A1 (es)
BR (1) BR112012007252A2 (es)
CA (1) CA2775880A1 (es)
CL (1) CL2012000800A1 (es)
CO (1) CO6531430A2 (es)
CR (1) CR20120213A (es)
EC (1) ECSP12011858A (es)
ES (1) ES2580229T3 (es)
HK (1) HK1170505A1 (es)
IL (1) IL218662A0 (es)
MA (1) MA33973B1 (es)
MX (1) MX342250B (es)
PE (1) PE20120998A1 (es)
RU (1) RU2012117619A (es)
WO (1) WO2011041336A2 (es)
ZA (1) ZA201201984B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2032166B1 (en) 2006-06-13 2013-04-10 OncoMed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
AU2008209482B2 (en) 2007-01-24 2014-05-01 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
JP5560270B2 (ja) 2008-07-08 2014-07-23 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｎｏｔｃｈ結合剤およびアンタゴニストならびにその使用方法
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
WO2010146550A1 (en) 2009-06-18 2010-12-23 Pfizer Inc. Anti notch-1 antibodies
BR112013015122A2 (pt) 2010-12-15 2017-05-30 Wyeth Llc anticorpos anti-notch1
MX2015005810A (es) * 2012-11-07 2015-09-23 Pfizer Anticuerpos anti-notch y conjugados de anticuerpo-farmaco.
DK2935330T3 (da) 2012-12-19 2019-07-22 Aveo Pharmaceuticals Inc Anti-notch3-antistoffer
WO2014159242A1 (en) * 2013-03-14 2014-10-02 Novartis Ag Notch 3 mutants and uses thereof
JP2016514130A (ja) * 2013-03-14 2016-05-19 ノバルティス アーゲー Ｎｏｔｃｈ３に対する抗体
KR20150130466A (ko) * 2013-03-15 2015-11-23 온코메드 파마슈티칼스, 인크. 췌장암을 치료하는 방법
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
PE20161335A1 (es) 2014-02-12 2016-12-07 Genentech Inc Anticuerpos anti-jagged1 y metodos de uso
JP2017526641A (ja) 2014-07-11 2017-09-14 ジェネンテック， インコーポレイテッド Ｎｏｔｃｈ経路阻害
CN105585636B (zh) * 2015-11-24 2020-03-03 南方医科大学 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用
EP3448420B1 (en) 2016-04-29 2022-09-14 Aveo Pharmaceuticals, Inc. Anti-notch3 antibody

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP1709970A1 (en) 1995-04-27 2006-10-11 Abgenix, Inc. Human antibodies against EGFR, derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
EA200701211A1 (ru) 2004-12-31 2007-12-28 Дженентек, Инк. Полипептиды, которые связываются с br3, и их применение
EP2081962B1 (en) * 2006-10-19 2018-10-03 Genentech, Inc. Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
AR063494A1 (es) 2006-10-19 2009-01-28 Genentech Inc Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
KR20150004933A (ko) 2006-12-18 2015-01-13 제넨테크, 인크. 항-ｎｏｔｃｈ3 길항제 항체 및 ｎｏｔｃｈ3-관련 질환의 예방 및 치료에 있어서 그의 용도
AU2008209482B2 (en) * 2007-01-24 2014-05-01 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
EP2134356A2 (en) * 2007-03-05 2009-12-23 Board of Regents, The University of Texas System Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
JP5560270B2 (ja) * 2008-07-08 2014-07-23 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｎｏｔｃｈ結合剤およびアンタゴニストならびにその使用方法
WO2010141249A2 (en) * 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-notch3 antibodies
WO2010146550A1 (en) * 2009-06-18 2010-12-23 Pfizer Inc. Anti notch-1 antibodies

Also Published As

Publication number Publication date
WO2011041336A2 (en) 2011-04-07
AU2010300747A1 (en) 2012-04-26
CN102630229B (zh) 2015-03-04
CO6531430A2 (es) 2012-09-28
JP2015145362A (ja) 2015-08-13
JP6025563B2 (ja) 2016-11-16
HK1170505A1 (en) 2013-03-01
CN102630229A (zh) 2012-08-08
PE20120998A1 (es) 2012-08-14
JP2017014219A (ja) 2017-01-19
ES2580229T3 (es) 2016-08-22
EP2483311A2 (en) 2012-08-08
ECSP12011858A (es) 2012-06-29
JP2013506675A (ja) 2013-02-28
MA33973B1 (fr) 2013-02-01
US20120328608A1 (en) 2012-12-27
MX2012003851A (es) 2012-05-08
US9200071B2 (en) 2015-12-01
KR20120100952A (ko) 2012-09-12
EP2483311B1 (en) 2016-05-18
RU2012117619A (ru) 2013-11-10
ZA201201984B (en) 2013-05-29
CR20120213A (es) 2012-07-09
IL218662A0 (en) 2012-05-31
CL2012000800A1 (es) 2012-08-31
KR101782180B1 (ko) 2017-10-23
WO2011041336A3 (en) 2012-05-03
BR112012007252A2 (pt) 2020-08-11
CA2775880A1 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
MX342250B (es) Tratamiento de cánceres resistentes a antagonistas notch1, mediante el uso de antagonistas notch3.
EP2569434A4 (en) COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA
IN2012DN02081A (es)
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
CR20120202A (es) Métodos y composiciones para tratar cáncer
EA201171367A1 (ru) Винилиндазолильные соединения
WO2011037643A3 (en) Compositions and methods for detecting and treating prostate carcinoma
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
MX2011007930A (es) Conjugados de insulina cristalina.
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
MX2010000465A (es) Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
AU2011338383A8 (en) Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1
MX2012010434A (es) Compuestos y composiciones novedosas para atacar a las celulas madre del cancer.
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
EA201270606A1 (ru) Новое противоопухолевое применение кабазитаксела
WO2010101793A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
MX2013002155A (es) Compuestos para el tratamiento de cancer.
FR2945210B1 (fr) Combinaison antitumorale comprenant l'ave8062 et le sorafenib
EP2249825A4 (en) TREATMENT PROCEDURES AND COMPOSITIONS AGAINST LUNG CANCER, ADENOCARCINOMA AND OTHER MEDICAL DISEASE STATES
MX2011006532A (es) Compuestos anticancerigenos.
WO2013070933A3 (en) Compositions and methods for the treatment of prostate carcinoma
WO2010002454A3 (en) Therapeutic combinations for use in neoplasia
TN2010000463A1 (en) Compositions and methods for preparing and using same
TN2011000013A1 (en) Amidophenoxyindazoles useful as inhibitors of c-met

Legal Events

Date Code Title Description
FG Grant or registration